It's interesting from a science perspective. Question for you: do you know what is different about it from the other cancer patents they have? I have done nearly zero research into their cancer potential outside of oral mucositis, so not sure what's new. It seems like antiangiogensis was the prior target, so they may have a few oars in the water in oncology... But the cash flow potential is way too far into the future to influence stock price for the next 3 years at least.
However, skimming the patent you linked, the broad spectrum of susceptible cancers and large markets were intriguing. The selectivity struck me as low, but not too sure about that one way or the other.
Could be promising in 2015 when brilacidin is approved by the FDA and investors are looking for what's next.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.